3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
3
Brain Neoplasms
2
Oligodendroglioma
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Castrate-resistant Metastatic Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Blood Specimen Collection
2
cabazitaxel
1
Watchful Waiting
1
Cetuximab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplastic Cells, Circulating
×
cabazitaxel
×
Clear all
NCT02621190
2016-08-17
CARVE
Erasmus Medical Center
Phase 2
Withdrawn